<SEC-DOCUMENT>0001571049-17-006801.txt : 20170719
<SEC-HEADER>0001571049-17-006801.hdr.sgml : 20170719
<ACCEPTANCE-DATETIME>20170719084427
ACCESSION NUMBER:		0001571049-17-006801
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170719
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170719
DATE AS OF CHANGE:		20170719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		17970860

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1702157_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of earliest event reported):
July 19, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>000-50626</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(State
        or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(IRS
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>200
Connell Drive, Suite 1500</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Berkeley Heights, NJ 07922 </B></FONT><BR>
<FONT STYLE="font-size: 8pt"><B>(Address of principal executive offices and zip code) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registrant&rsquo;s telephone number, including
area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Former Name
or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction
A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter). <FONT STYLE="font-family: Wingdings">&#168;</FONT></B></P>

<P STYLE="font: 10pt inherit,serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </B></FONT><B><FONT STYLE="font-family: Wingdings">&#168;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 8.01</B></TD><TD STYLE="text-align: justify"><B>Other Events.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On July 19, 2017, Cyclacel Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) issued a press release announcing the pricing of an underwritten public offering of Class A Units
and Class B Units pursuant to a registration statement filed on Form S-1 (File No. 333-218305) with the Securities and Exchange
Commission, which was declared effective on July 18, <FONT STYLE="text-underline-style: double">2017 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
an additional registration statement filed pursuant to Rule 462(b).</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
The offering is comprised of (i) Class A Units, with each unit consisting of one share of the Company&rsquo;s common stock, par
value $0.001 per share (the &ldquo;Common Stock&rdquo;) and a seven-year warrant to purchase one share of Common Stock, and (ii)
Class B Units, with each unit consisting of one share of the Company&rsquo;s Series A Preferred Stock, par value $0.001 per share
(the &ldquo;Preferred Stock&rdquo;) and </FONT><FONT STYLE="text-underline-style: double">seven-year warrants</FONT>
to purchase a number of shares of Common Stock equal to $1,000 divided by the conversion price. In addition, the Company has granted
the underwriters an option for a period of 45 days to purchase additional shares of Common Stock and/or warrants solely to cover
any over-allotments at the public offering price per share and per warrant, less the underwriting discounts and commissions. The
closing of the offering is expected to take place on or about July 21, 2017, subject to the satisfaction or waiver of customary
closing conditions. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 9.01</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify"><U>Exhibits</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Exhibit</B><BR>
    <B>No.</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 88%; border-bottom: Black 1pt solid; text-decoration: none; text-align: center"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Press release, dated July 19, 2017,
        announcing pricing of underwritten public offering.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 42%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: July 19, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1702157_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: left"><IMG SRC="t1702157_logoex99-1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel Pharmaceuticals, Inc.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><IMG SRC="t1702157_pg1ex99-1.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CYCLACEL ANNOUNCES PRICING OF $13.2 MILLION
UNDERWRITTEN PUBLIC OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Berkeley Heights, NJ, July 19, 2017 </B>&ndash;
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell
cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other
proliferative diseases, today announced the pricing of an underwritten public offering of units for gross proceeds of $13.2 million,
prior to deducting underwriting discounts and commissions and offering expenses payable by Cyclacel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The offering is comprised of Class A Units,
priced at a public offering price of $2.00 per unit, with each unit consisting of one share of common stock and a seven-year warrant
(each, a &ldquo;warrant&rdquo;) to purchase one share of common stock with an exercise price of $2.00 per share, and Class B Units,
priced at a public offering price of $1,000 per unit, with each unit comprised of one share of preferred stock, which is convertible
into 500 shares of common stock, and warrants to purchase 500 shares of common stock with an exercise price of $2.00 per share.
The conversion price of the preferred stock issued in the transaction and the exercise price of the warrants are fixed and do not
contain any variable pricing features or any price based anti-dilutive features. The preferred stock issued in this transaction
includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common
stock), liquidation preference or other preferences over common stock, and, with certain exceptions, has no voting rights. The
securities comprising the units are immediately separable and will be issued separately. The closing of the offering is expected
to take place on or about July 21, 2017, subject to the satisfaction or waiver of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ladenburg Thalmann &amp; Co. Inc., a subsidiary of Ladenburg Thalmann
Financial Services Inc. (NYSE MKT: LTS), is sole book-running manager in connection with the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A total of 2,164,000 shares of common stock, 8,872 shares of preferred
stock convertible into 4,436,000 shares of common stock, and warrants to purchase 6,600,000 shares of common stock will be issued
in the offering.  If exercised in full, the warrants could result in additional net financing proceeds to Cyclacel of $13.2
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Cyclacel has granted the underwriters
a 45-day option to purchase up to 990,000 additional shares of common stock and/or additional warrants to purchase up to 990,000
shares of common stock solely to cover over-allotments, if any, at the public offering price per share and per warrant, less the
underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities were offered pursuant to a registration
statement on Form S-1 (File No. 333-218305), which was declared effective by the United States Securities and Exchange Commission
(&quot;SEC&quot;) on July 18, 2017, and an additional registration statement filed pursuant to Rule 462(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release does not constitute an offer
to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
A final prospectus relating to this offering will be filed by Cyclacel with the SEC. When available, copies of the final prospectus
can be obtained at the SEC&rsquo;s website at www.sec.gov or from Ladenburg Thalmann &amp; Co. Inc., Prospectus Department, 277
Park Avenue, 26<FONT STYLE="text-transform: uppercase"><SUP>th</SUP></FONT> Floor, New York, New York 10172, by calling (212) 409-2000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Wingdings">&thorn;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922, USA Tel +1 (908) 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
1 James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>www.cyclacel.com</U> &ndash; <U>info@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cyclacel Pharmaceuticals is a clinical-stage
biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative,
targeted medicines for cancer and other proliferative diseases. Cyclacel's transcriptional regulation program is evaluating CYC065,
a CDK inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine
and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel is analyzing stratified and
exploratory subgroups from a Phase 3 study of sapacitabine in elderly patients with AML. Cyclacel's strategy is to build a diversified
biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information,
please visit <U>www.cyclacel.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that
include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot;
&quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot;
&quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot; or the negative of those
words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties
the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with
the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Contacts</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 25%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company:</font></td>
    <td style="width: 75%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul McBarron, (908) 517-7330, <u>pmcbarron@cyclacel.com</u></font></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Relations:</font></td>
    <td style="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russo Partners LLC,
    Alexander Fudukidis, (646) 942-5632,</FONT><br>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>alex.fudukidis@russopartnersllc.com</U></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&copy; Copyright 2017 Cyclacel Pharmaceuticals,
Inc. All Rights Reserved. The Cyclacel logo and Cyclacel<SUP>&reg;</SUP> are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>t1702157_logoex99-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1702157_logoex99-1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 1 "U P$1  (1 0,1 ?_$ *@  0 " P$!  ,
M       ("08'"@4$ 0(# 0$  04! 0$             !@,$!0<("0(!$
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MDB) *8\3;F***W0QNX#E,(!]>;YY$<.Z.,=K;S9]3\)IS$RCXE+D<]R-J/\
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MY3KK +CQ-EU7)G2E7):198W[RTUR%,[OZF8OU*;-SU@F*ZE2<^,<\6N6(O\
MF UN7O,I P$/6(?X12196*;-5R94RCD5!*!$^Y2H5Y(TVV'L'O\ -=]XHJD-
M7.L]"T3O>%K1?AM%81=1^1INVW*4CH(M26E4[8\3792S<_RD6:C4O>(&4*)1
M#BE2.]K'K<K7LOUQC\9DO4EAW-F*KU YHUJSG"-U'4KBC,E0.=6"F5&J#AHY
M?04DF<S9\DDJFJ0#)N41\[9+BE0=J&PO]1=B.OP6,LB^NW4S:^WQ3$L0OL?C
MG<*#PW3K2=D<6Z%EM&-[G32V2*E))HD"[I*-;IMC.#CX44$^B9%*U7[0]=O9
MMD78OT\;IX*U,Q]GO,&G\;ERV[ 8C@L[U#&]'C,@9)HU#@G-;J]YR,XC966K
MS253DQ:/B1ZRJB3),5DDQ6#HI4JZ3M5[I,C8SV>:7_U9U'7G($)KQ=I36V1A
M=QL.Y7->=@'2T="4FIR;)%*"CJY#,B2J\RY?O7!4!2BS-PZJKIAQ2M'Z'?TZ
MV@N.]1<&US<C4O$&;=JUJB%GV"R5<"OK/.S>5;I(OK;;&"LZUER,I-E5I"9&
M):K(%!)9NQ(J'<90QS*5^</>KVV^OCW T?-NAV :U5M =C]:)3#VUU&J%BK$
M##XQR939>2L6/,F,ZA9; A.60LT<6L>J6-2<G;).9!4X?S2D.I6!4;0KV8>I
M3,6<ICU?0.#]L=(\]WVQ9?<:69FR"_PK=\&9(L:J)I4F%LDKLIBHJ5)^BDDD
M9"0*0?C-44A1\R0O%U*GKBN_^T#9G%^SU3VJT>Q+JC V37_(57Q/!5_9F!S?
MD*UY(L=>D89C'SKFO0</2:W73H/3 "YW9U07[>[HGW&!2J?/6Y,^^[UV:6X8
MT\BO3?C_ "LSPZQM3-O?GF^^#J@YL/YGNUDNAE7%=2)84HXS,]B%L $=J@<J
M('_")A*"E;Z]M>M'LAS9LOZ<-W-;-0(#+60M1$<CY(SAA%_GO&]$CZO>;W"8
MD5+0$+]9I!DWG6K"3B95N$G'LW2)_@E.*8%6)Q2K(M+MG_:?E[,3BI[D>LRG
MZD8B3ILW+(95@]N\;YP?+W!F^AT86J#3*G%LY--"79.WBQGHG\2 M0*8!%0O
M12K7^*5!K<G&]S;+8YVCP[%+3&7-<7\E*NJLQ 2O<HX?FT4TLF8U2[2F\\H[
MCFY7\4!@-V2#4"D#O5 >;;XOSN*<3.X^W.X&MM9Q"4!U7RQ)K9)BRC\$!1+;
MUK7;7<]$UHCFG;.;;7C>5=F-%[>&VG%N*83\T['.@";#%O%Q2!W8]P;.HLD:
ME@UZ5H81^R%.Q3M1K%9H<V1JO&NI>@2D@HHUA+Q5IDJ07#"V2"M@4>1\;+.F
M14U.XAW$%-LTG!2"9)1-2CCWGMBY3(\>;_CN_0Y#@1(0FQ<8=1?LSHM[)4I
M42+$)D,+4@FRDJ3<96/'Y+PV(Y8XME,G<L1I3D1:R4M2F'+>YQLW3=2$.*2
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MS(:[3:NMT6K'/[ V_CT_NGE++NY<Q#W=<];3&.C*3U[C<- ;BI*?RN/]]U)
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(<4IQ2G%*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>t1702157_pg1ex99-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1702157_pg1ex99-1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ %P)- P$1  (1 0,1 ?_$ &\  0 " @(# 0
M       '" 8) 04" P0* 0$                     $   !0,$ 00" P !
M!0     ! @,$!0 &!]075Y<1(1(3"#$402(C%5%A%A@)$0$
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MW>C:/C EH:0G#M3R-OE0$/UW<(Y_33]Y3_V-[?7T$0$+H$ P%*!S <X% #&
MOM Q@ /<8"^1]H"/KX\CXH/*@K#DKZY/KWRK&Y>MO*ES8ZNJ,M,;1;JP<-;\
MJ3]!1T\<N%!"<:NT_D7_ &_:(>P? $ 0$!H+*,D%FS)HV<.E'SANU;H+O5B)
MIJO%DDB)JNE4T2D134<'*)S%* % 1\ 'B@^J@KKFS!$UF8YH\V7KULVSI&'3
MA+ELVWVL*I&S[0'BKI955T]:*O6CITFH"*ABF,0R1"@)1#SY":[5MB'LNVH*
MTK>;?IPEN13*'BVPG,H9)DP0(W1!14W]E53%)Y.8?4QA$1_-!W]!"&9<2W)E
M5HUCH?+5W8WC#1\K$ST?;;.'=M[CCY8J*3A)X:2;J+MEDD$SIIJ)'*)2JG\@
M/F@S7&F/+=Q38UNX_M5)=.#MMD+1H9TJ"SMP=595T[>.U@*0JCEX\745.(%*
M4#&\% "@  &=4"@4"@KC>_ULM3(&39C(MQ2CYRA.XKD<52-KBU9FCE8R1<N'
M1I0CLY3.TI%LJN!DO']2'(4P>H4$BXCQ^YQ9C^W[!7NF3O!&VFQH^-F9ALU;
M2/\ Q29Q&/CUP:#\2I8U 013/Z&%(A0'\>:"2:"%<]X7C\\6(2QI*?D;;03G
MXB?3DXMLT=NBN(<RQT4@1> * IJ&6\B/Y#Q09;CJU;DL^"5BKHO^:R/('D5W
M:4[.QL-%O$&:B#9)&,*W@VK1H=!N= YP.8HJ&%4?(B !09[01+F_$T?F_'$U
MCB4F'L$RFEXM=62CT&[ETB,9)-I$A4T77^)@6.V H^?P ^0]:#L<76/<%@6\
M:!G\@360SI+I!'24Y&0T6XC8U!FV9MXI%*%:M45D$?UQ.!U ,J(G'R(^E!)-
M!%6:L5L,U8WN#&\I+/81C<'_ !X+R4>@W<.T 82+61*"23G_ !-\IVH%'S^
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M,EJ9>NJRI2\"VZVGH>,@[;?L7L;;[6.:DCC+RS1TX32> P\G.3VJ%%0?:/@
MH+3T"@4"@4"@4"@4"@4"@4"@4"@4"@@Y7.*22JJ6TV<5/B542^1+'+LZ2GQG
M,3Y$C_NA[TC^WR4?Y 0&@]>^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFN
MH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=
M>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^
MJ7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MW
MFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$
M>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH
M&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>
MMWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J
M7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWF
MNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>
M=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&
M^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>M
MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7
M$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFN
MH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=
M>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH&^J7$>=>MWFNH.0
DSFD)3&VDSH'M,0O@<<._<;W@<?)0_>]2E]GJ/\>0_P"M!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
